1. Home
  2. TTRX vs CD Comparison

TTRX vs CD Comparison

Compare TTRX & CD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

SELL

Current Price

$11.11

Market Cap

298.8M

Sector

Health Care

ML Signal

SELL

Logo Chaince Digital Holdings Inc. Ordinary Shares

CD

Chaince Digital Holdings Inc. Ordinary Shares

HOLD

Current Price

$7.18

Market Cap

323.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTRX
CD
Founded
2015
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
323.4M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
TTRX
CD
Price
$11.11
$7.18
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.00
N/A
AVG Volume (30 Days)
145.0K
★ 250.3K
Earning Date
11-25-2026
08-31-2023
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,867,068.00
Revenue This Year
N/A
N/A
Revenue Next Year
$900.00
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 277.93
52 Week Low
$2.57
$2.10
52 Week High
$16.45
$14.10

Technical Indicators

Market Signals
Indicator
TTRX
CD
Relative Strength Index (RSI) 42.42 56.62
Support Level $9.02 $3.53
Resistance Level $14.39 $8.89
Average True Range (ATR) 1.25 1.63
MACD -0.41 0.26
Stochastic Oscillator 1.09 36.72

Price Performance

Historical Comparison
TTRX
CD

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About CD Chaince Digital Holdings Inc. Ordinary Shares

Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.

Share on Social Networks: